Navigation Links
Cordex Pharma Sets Fourth Quarter 2008 Program Update Call
Date:2/13/2009

Conference call scheduled for Friday, February 20, at 10:00 a.m. EST

LA JOLLA, Calif., Feb. 13 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) will host a teleconference on Friday, February 20, at 10:00 a.m. EST to provide a fourth quarter business review and drug development update. Cordex's Chief Executive Officer, James S. Kuo, M.D., M.B.A., will give the presentation and there will be a question-and-answer session immediately afterwards.

To participate in the teleconference, please call toll-free 800.894.5910 (direct dial 785.424.1052) five minutes prior to the scheduled starting time in order to register for the call.

A replay of the call will be available after the call's completion for ten days at 800.283.8520 (direct dial 402.220.0870).

About Cordex Pharma, Inc.

Cordex is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex has a portfolio of investigational medicines, two of which are in late stages of clinical development. Cordex's ATPace is expected to enter a Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia in 2009. Cordex's CDP-1050 is also expected to commence a Phase 2 clinical trial for the treatment of heart failure in 2009. In addition, Cordex has a preclinical program to develop new chemical entities that target a recently discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For further information regarding Cordex, please visit the company's website at www.cordexpharma.com.

Forw
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Combination Products Executive Forum to be Hosted by CHI's Pharmaceutical Strategy Series
2. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2008 Financial Results Teleconference and Webcast
3. Union Springs Pharmaceuticals Introduces New, More Effective Respirator
4. URAC Calls for Public Comment on Revisions to its Pharmacy Benefit Management (PBM) and Drug Therapy Management (DTM), Version 2.0 Standards and NEW Performance Measures, and PHARM Core, Version 3.0 Standards
5. Shengtai Pharmaceutical Schedules 2009 Second Quarter Financial Results and Conference Call
6. ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter and Full-Year 2008 Financial Results
7. Managing Myeloma (www.managingmyeloma.com) Launches - A Comprehensive Information and Educational Site for Physicians, Nurse Practitioners, Physician Assistants, and Pharmacists
8. Otsuka America Pharmaceutical, Inc. Announces the Appointment of Mark Altmeyer as President and Chief Executive Officer
9. DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease
10. Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel
11. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... April 17, 2015 As a board-certified ... his new offering of platelet-rich plasma (PRP) ... (MOSM) is known for its world-class care of ... extensive surgical experience lacking in many other physicians offering ... treatments are utilized for pain management and rehabilitation. Dr. ...
(Date:4/17/2015)... 2015 Baptist Health and The University ... partnership agreement designed to transform oncology care in northeast ... agreed to create a joint cancer program to enhance ... research. Baptist MD Anderson Cancer Center is anticipated to ... destination for highly coordinated, multidisciplinary cancer care for adults ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Connie Casad, ... and functional medicine advocate with 30 years of practice ... be adding another level of service for her patients ... website of 10 recommended wellness books with a brief ... asked to explain her interest in providing this service, ...
(Date:4/17/2015)... 17, 2015 Oxytocin is ... pituitary and thought to help mothers bond to their ... further substantiate this, new studies performed, at NYU Langone ... and reported by Medical News Today on April 16, ... over maternal social behavior. The study reveals that, when ...
(Date:4/17/2015)... NY (PRWEB) April 17, 2015 Ticket Down is ... for their 2015 Summer Tour. , The life of last-minute show ... see the popular group perform during the early part of 2015, ... “I Will Wait,” “Little Lion Man,” “The Cave,” and “Believe,” will ... off on June 2 at MCU Park at Coney Island in ...
Breaking Medicine News(10 mins):Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3Health News:Connie Casad, M.D. Provides Patients Recommended List of Wellness Books on Website 2Health News:Oxytocin Now Found to Help Diet Doc Patients Whose Weight Has Gotten out of Control Due to Emotional Eating Disorders 2Health News:Oxytocin Now Found to Help Diet Doc Patients Whose Weight Has Gotten out of Control Due to Emotional Eating Disorders 3Health News:Mumford and Sons Tickets in Clarkston/Detroit, Raleigh, Columbia/Baltimore, Chicago, Mansfield/Boston, Brooklyn, Calgary and Edmonton Now On Sale 2
... to a report published in the December issue of the ... residents improved their knowledge of health care business concepts and ... expectation is for residents to "demonstrate an awareness of and ... as well as the ability to call effectively on other ...
... of synthetic molecules to fish for disease-specific antibodies, researchers have ... simple blood test. The same methodology might lead to blood ... the January 7th issue of the journal Cell , ... disease, it suggests it is a pretty general platform that ...
... study to date of "Sarcoid Like" Granulomatous Pulmonary Disease in ... of the condition was increased in this group as compared ... published online in the American Journal of Industrial Medicine ... responders who had an initial exam in the Mount Sinai ...
... the first robotic assisted surgery for prostate cancer in ... Vattikuti Institute. Today, the majority prostate of cancer ... than 6,000 procedures have been performed during the past ... field will meet at the world,s largest medical robotic ...
... most widely produced fruit in the world and now ... nutrient which could tackle the onset of vascular diseases. ... & Food Research , reveals that an extracted compound, ... led by Dr Teruo Kawada, from Kyoto University and ...
... brain against developing Alzheimer,s and other forms of dementia, according ... study, published in the academic journal Phytomedicine , also ... in protecting the body against cancer., Led by Dr Ed ... properties of green tea which have previously been shown ...
Cached Medicine News:Health News:Web-based curriculum improves surgical residents' knowledge of health care business 2Health News:A blood test for Alzheimer's disease? 2Health News:A blood test for Alzheimer's disease? 3Health News:Study of 'sarcoid-like' granulomatous pulmonary disease finds elevated rates in WTC responders 2Health News:Study of 'sarcoid-like' granulomatous pulmonary disease finds elevated rates in WTC responders 3Health News:10 years later: Robotic surgery for prostate cancer 2Health News:Protective properties of green tea uncovered 2
(Date:4/17/2015)... , April 17, 2015  In Detroit, where three ... mortality rate is two and one half times of the ... 6 of 10 infants that die in Detroit ... sobering statistics that Covenant Community Care, a faith-based, charitable non-profit ... poised to change thanks to a charitable donation by Konica ...
(Date:4/17/2015)... , April 17, 2015  Over the next five years, ... to grow, with ArcView predicting that 14 more states will ... marijuana. The U.S. market for legal cannabis grew 74 percent ... 2013. Analysts project the market could grow more than fourfold ... states soften their stance on marijuana. Cannabiz Mobile ...
(Date:4/17/2015)... and Markets ( http://www.researchandmarkets.com/research/7qs3dw/corporate ) has announced ... in 2014 - a Perspective of Diabetes Patient Groups ... This independent study, funded by the author, represents ... in diabetes on the corporate reputation of 14 individual ... whole) in 2014. The results from the respondent diabetes ...
Breaking Medicine Technology:Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 2Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 3Covenant Community Care to Receive Donated SONIMAGE P3 Handheld Ultrasound from Konica Minolta Medical Imaging 4Cannabiz Mobile Analyst Brief: Next Big Thing by Torus IR Issued by BrokerBank Securities, Inc. 2Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 2Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 3Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 4Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 5
... 23, 2007 /PRNewswire-FirstCall/ -- Shire plc,announced that ... non-oral medication approved for treatment of,Attention Deficit ... 12 years, provided significant improvement in symptom ... 12-month open-label,study presented at the American Psychiatric ...
... Underscores Impact of Disease on Work Status and,Productivity, ... at Digestive Disease Week(R) 2007 (DDW), from,long-term extensions ... 2) show that subjects with moderately to severely ... in the blinded phase of the trials maintained,improvement ...
Cached Medicine Technology:12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 212-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 312-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 412-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 512-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 612-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 712-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 812-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 9Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 2Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 3Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 4Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 5Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 6Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 7Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 8Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 9
Biopro rimmed acetabular is manufactured from titanium and is porous coated on the outside of its shell. The rimmed acetabular accommodates a polyethylene inert....
The Plasmacup SC satisfies two important requirements: high primary stability and a low friction bearing surface....
The cementless acetabular shells form part of the Mallory head range of femoral and acetabular implants....
Trident Hemispherical Acetabular Shells are a true hemispherical shape designed to achieve press-fit fixation by under-reaming the acetabulum....
Medicine Products: